Originally published in February 2004. This guideline is more than 5 years old and has not
yet been updated to ensure that it reflects current knowledge and practice. In accordance …

The treatment of schizophrenia has evolved over the past half century primarily in the
context of antipsychotic drug development. Although there has been significant progress …

1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor,
schizophrenia remains a chronic, disabling disorder for most affected individuals. 2. Studies …

OBJECTIVE: Research has implicated dysfunction of glutamatergic neurotransmission in the
pathophysiology of schizophrenia. This review evaluates evidence from preclinical and …

While the dopamine hypothesis has dominated schizophrenia research for several decades,
more recent studies have highlighted the role of fast synaptic transmitters and their receptors …

Schizophrenia is a serious mental disorder that affects up to 1% of the population worldwide.
As of yet, neurochemical mechanisms underlying schizophrenia remain unknown. To date …

Glutamate is the primary excitatory neurotransmitter in the mammalian brain. Glutamatergic
neurotransmission may be modulated at multiple levels, only a minority of which are …

Abstract D-Cycloserine (CYC), a partial N-methyl-D-aspartate (NMDA) agonist, has been
shown to improve cognitive functions in humans. However, the neurophysiological basis of …

Welcome to the fifth edition of a very handy and useful book, the Manual of Clinical
Psychopharmacology. Readers familiar with any of the previous editions are already aware …

Abstract Objective: On April 23, 2004, a joint meeting of the FDA, NIMH, MATRICS
investigators, and experts from academia and the pharmaceutical industry was convened to …